menu
    • menu
    [{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mesoblast \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Inapplicable"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Gregory George","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Immunology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mesoblast \/ Gregory George","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Gregory George"}]

    Find Immunology Drugs in Phase III Clinical Development in AUSTRALIA

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Gregory George

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch

                            Details : The proceeds will be used in Mesoblast’s lead product candidate Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD).

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 29, 2024

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Gregory George

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mesoblast Resubmits BLA for Ryoncil® in Children with Steroid-Refractory aGVHD

                            Details : Ryoncil (remestemcel-L) is an investigational therapy comprising mesenchymal stromal cells, for the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 07, 2024

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts BLA for Mesoblast’s Ryoncil® in Pediatric Acute Graft-Versus-Host Disease

                            Details : Ryoncil (remestemcel-l) have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines.

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Notifies Mesoblast That Phase 3 Data Supports BLA for SR-aGVHD in Children

                            Details : Prochymal (remestemcel-L) is an off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells, evaluated for pediatric patients with SR-aGVHD.

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : BMT CTN

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mesoblast Partners with Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adul...

                            Details : The agreement aims to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil (remestemcel-L) in the treatment of adults with steroid-refractory acute graft versus host disease (SR-aGvHD).

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 21, 2023

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : BMT CTN

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval

                            Details : Ryoncil (remestemcel-l) have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved...

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            September 21, 2023

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Mesoblast’s Resubmission of The Biologic License Application for Remestemcel-L in Children with ...

                            Details : Remestemcel-L have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $40.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Mesoblast Completes Private Placement

                            Details : The net proceedings will be used to fund the launch and commercialization of the company’s lead product, Prochymal (remestemcel-L), in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 25, 2023

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $40.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mesoblast Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application ...

                            Details : Remestemcel-L have immunomodulatory properties to counteract the inflammatory processes in SRaGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of naturally occurring anti-inflammatory cells to involved tissues.

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 08, 2023

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refra...

                            Details : Remestemcel-L is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SRaGVHD by down-regulating pro-inflammatory cytokines, increasing production of antiinflammatory cytokines.

                            Product Name : Ryoncil

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Remestemcel-L

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth